	The safety of trastuzumab deruxtecan (T-DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta-analysis. Cancer Ma Y, Li X, Jiang Y, Xiao L, Sun T. PMID: 41620925 [PubMed - indexed for MEDLINE]
	Metabolomic-driven prediction of the mutational status of healthy individuals with a family history of hereditary breast and ovarian cancer syndrome: the HRRmet study. Sci Rep Roig B, Fernández-Castillejo S, Gumà J, Badia J, Melé M, Salvat M, Querol M, Cumeras R, Rodríguez-Balada M. PMID: 41620477 [PubMed - as supplied by publisher]
	[French recommendations for clinical practice, Nice-Saint-Paul de Vence 2024-2025: Management of high-grade ovarian epithelial cancer]. Bull Cancer Selle F, Rodrigues M, You B, Gladieff L, Hardy-Bessard AC, de la Motte Rouge T, Fumet JD, Le Saux O, Colombo PE, Ferron G, Treilleux I, Rouleau E, Falandry C, Joly F, Frénel JS, Quesada S, Classe JM. PMID: 41620325 [PubMed - as supplied by publisher]
	[Breast implants and cancer: Anaplastic large cell lymphoma in breast implants]. Ann Chir Plast Esthet Bosc R, Dao TH, Haioun C. PMID: 41620260 [PubMed - indexed for MEDLINE]
	Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial. Lancet Gommers J, Hernström V, Josefsson V, Sartor H, Schmidt D, Hjelmgren A, Larsson AM, Hofvind S, Andersson I, Rosso A, Hagberg O, Lång K. PMID: 41620232 [PubMed - indexed for MEDLINE]
	The emerging role of nicotinamide N-methyltransferase in the pathogenesis and treatment of breast cancer. Biochem Pharmacol Bi SZ, Ni XL, Sun WD, Zhang CY, Liu A, Lai SY, Li JH. PMID: 41620136 [PubMed - as supplied by publisher]
	Tumor microenvironment and biomarker innovation in ovarian cancer: mechanistic insights into immune evasion, angiogenesis, and therapeutic resistance. Clin Chim Acta Liu Y, Zhang L, Wang Q, Li X, Feng X. PMID: 41620003 [PubMed - as supplied by publisher]
	Menopausal hormone treatment and breast cancer. Lancet Diabetes Endocrinol Gompel A, Simcock R. PMID: 41619758 [PubMed - as supplied by publisher]
	Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2. Breast Mazzoli G, Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Fotia G, De Monte M, Ligorio F, Jacobs F, Armani G, Zurlo C, Menichetti A, Griguolo G, Faso V, Schianca AC, Munzone E, Marra A, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, PALMARES-2 study group, Vernieri C. PMID: 41619649 [PubMed - as supplied by publisher]
	CDK4/6 Inhibitors in HER2-positive Metastatic Breast Cancer. Clin Breast Cancer Bischoff H, Petit T. PMID: 41619606 [PubMed - as supplied by publisher]
	Triple Technique (Radioisotope, Blue Dye, and Embedded Fiducial Marker) for Identifying Sentinel Lymph Nodes Following Neoadjuvant Chemotherapy for Clinical Lymph Node Positive Breast Cancer; Is More Really Better? Clin Breast Cancer Sarah F, Jacienta P, Richard H, Lisa W, Luona S, Roshni R, Bret T. PMID: 41619605 [PubMed - as supplied by publisher]
	The effect of arm massage on the success of peripheral intravenous catheter insertion in breast cancer patients undergoing chemotherapy: A randomized controlled study. Eur J Oncol Nurs Eren H, Karacan Y. PMID: 41619401 [PubMed - as supplied by publisher]
	Male breast health and breast cancer risk. Maturitas Khatri L, Fraker J, Pruthi S. PMID: 41619336 [PubMed - as supplied by publisher]
	Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study. Int J Clin Oncol Takamatsu Y, Horimoto Y, Miyoshi Y, Watanabe J, Kutomi G. PMID: 41619158 [PubMed - as supplied by publisher]
	Healthcare cost for non-hospital services and pharmaceuticals among breast cancer survivors: an event study. Eur J Health Econ Dhingra A, Gannon B, Cheng TC, Connelly L, Mishra G. PMID: 41619146 [PubMed - as supplied by publisher]
	Hereditary ovarian cancer in women with African ancestry: a scoping review. Fam Cancer Rossouw B, Araujo M, Krause A, Baine-Savanhu F. PMID: 41619087 [PubMed - in process]
	Radiation therapy combined with tyrosine kinase inhibitors in 826 patients with HER2-positive breast cancer brain metastases: a systematic review and network meta-analysis. Neurosurg Rev Zare A, Khaboushan AS, Mohammadzadeh I, Mortezaei A, Zare A, Hajikarimloo B, Ghalehtaki R, Park DJ, Chang SD. PMID: 41619052 [PubMed - indexed for MEDLINE]
	Self-collected biospecimen consent and return rates in a population-based study among women with ovarian cancer: insights from the ORCHiD study. Cancer Causes Control Deveaux A, Neish D, Joshi A, Samuels S, Osazuwa-Peters OL, Duck V, Williams A, Kuliszewski MG, Huang B, Ward K, Pisu M, Tucker T, Previs R, Berchuck A, Akinyemiju T. PMID: 41619026 [PubMed - indexed for MEDLINE]
	Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia. Asia Pac J Clin Oncol Redfern A, Lim E, Lakhani S, Pathmanathan N, Selva-Nayagam S, McCarthy N, Yeo B, Dessauvagie B, Farshid G. PMID: 41618680 [PubMed - as supplied by publisher]
	Medication adherence in a German cohort of patients with advanced or metastatic breast cancer: results of the BRE-BY-MED study. BMC Cancer Brandstetter LS, Grau A, Müller-Reiter M, Salmen J, Müller-Nordhorn J, Beck N, Heuschmann P, Störk S, Wöckel A, Reese JP. PMID: 41618225 [PubMed - as supplied by publisher]

Articles 1 - 20 / 323728

Page 1 of 16187



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy